Compare INVZ & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVZ | ZURA |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.5M | 252.9M |
| IPO Year | N/A | N/A |
| Metric | INVZ | ZURA |
|---|---|---|
| Price | $1.30 | $3.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $3.10 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 5.0M | 405.5K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,442,000.00 | N/A |
| Revenue This Year | $146.75 | N/A |
| Revenue Next Year | $53.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.09 | N/A |
| 52 Week Low | $0.48 | $0.97 |
| 52 Week High | $3.14 | $4.68 |
| Indicator | INVZ | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 51.06 |
| Support Level | $1.24 | $3.66 |
| Resistance Level | $1.38 | $3.94 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 59.62 | 42.86 |
Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.